Literature DB >> 7808586

Expression of utrophin (dystrophin-related protein) during regeneration and maturation of skeletal muscle in canine X-linked muscular dystrophy.

L A Wilson1, B J Cooper, L Dux, V Dubowitz, C A Sewry.   

Abstract

The regulation of utrophin, the autosomal homologue of dystrophin, has been studied in the canine X-linked model of Duchenne muscular dystrophy. Dystrophic muscle has been shown to exhibit abnormal sarcolemmal expression of utrophin, in addition to the normal expression at the neuromuscular junction, in peripheral nerves, vascular tissues and regenerating fibres. To establish whether this abnormal presence of utrophin in dystrophic muscle is a consequence of continued expression following regeneration, or is attributable to a disease related up-regulation, the expression of utrophin was compared immunocytochemically with that of dystrophin, beta-spectrin and neonatal myosin in regenerating normal and dystrophic canine muscle, following necrosis induced by the injection of venom from the snake Notechis iscutatis. In normal regenerating muscle, sarcolemmal utrophin and dystrophin were detected concomitantly from 2-3 d post-injection, prior to the expression of beta-spectrin. Down-regulation of utrophin was apparent in some fibres from 7 d, and it was no longer present on the extra-junctional sarcolemma by 14 d. Neonatal myosin was still present in all fibres at this stage, but dystrophin and beta-spectrin had been fully restored. In dystrophic regenerating muscle, down-regulation of utrophin occurred from 7 d, although it persisted on some fibres until 28 d, longer than in normal muscle. At 42 d, however, utrophin in dystrophic muscle was only detected in a population of small fibres thought to represent a second cycle of regeneration, with no immunolabelling of mature fibres.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808586     DOI: 10.1111/j.1365-2990.1994.tb00981.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  7 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

2.  Alpha7beta1 integrin does not alleviate disease in a mouse model of limb girdle muscular dystrophy type 2F.

Authors:  Derek J Milner; Stephen J Kaufman
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Pathological pattern of Mdx mice diaphragm correlates with gradual expression of the short utrophin isoform Up71.

Authors:  Karim Hnia; Sylvie Tuffery-Giraud; Marianne Vermaelen; Gerald Hugon; Delphine Chazalette; Ahmed Masmoudi; François Rivier; Dominique Mornet
Journal:  Biochim Biophys Acta       Date:  2006-03

4.  Relaxin regulates MMP expression and promotes satellite cell mobilization during muscle healing in both young and aged mice.

Authors:  Xiaodong Mu; Maria L Urso; Kiley Murray; Freddie Fu; Yong Li
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

5.  Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy.

Authors:  Laurin M Hanft; Daniel J Bogan; Ulrike Mayer; Stephen J Kaufman; Joe N Kornegay; James M Ervasti
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

Review 6.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

7.  Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.

Authors:  Narinder Janghra; Jennifer E Morgan; Caroline A Sewry; Francis X Wilson; Kay E Davies; Francesco Muntoni; Jonathon Tinsley
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.